Wuxi BiologicsPartnershipSwiss AB2 Bio inks US$ 686m license option deal with Nippon ShinyakuLatest NewsNippon Shinyaku has secured an option to acquire exclusive US rights to commercialize AB2 Bio’s tadekinig alfa to treat primary monogenic IL-18 driven hyperinflammatory syndrome in patients with NLRC4 mutation and XIAP deficiency. Read more 27 January 2025 https://european-biotechnology.com/wp-content/uploads/2025/01/AB2-BIO.jpg 750 1333 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2025-01-27 10:05:102025-01-27 10:05:10Swiss AB2 Bio inks US$ 686m license option deal with Nippon Shinyaku